Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires

Page 8 of 14

7. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders In Q3 2024: 70

Bristol-Myers Squibb Company (NYSE:BMY) is a well-diversified drug manufacturer whose products cover ailments such as cancer, heart diseases, and immune system disorders. Its shares have gained 12% over the past year despite headwinds for the broader healthcare sector. Part of the optimism is due to Bristol-Myers Squibb Company (NYSE:BMY)’s older drug portfolio, which has treatments such as Eliquis and Revlimid helping the firm beat earnings estimates. Another strong Bristol-Myers Squibb Company (NYSE:BMY) drug is its schizophrenia medicine COBENFY. COBENFY was at the center of Cramer’s attention as he shared:

“Because Bristol Myers currently has Cobenfy, that’s just been approved, FDA, exactly for some of these indications that Intra-Cellular is supposed to be good for.

“But I want to hear what Bristol says, because Bristol’s got the one that everybody is buzzing about. Which is Cobenfy. Not what Intra-Cellular has.”

Page 8 of 14